-
1
-
-
4644362706
-
Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies
-
Ocean AJ, Vahdat LT Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004 ; 12: 619-625.
-
(2004)
Support Care Cancer
, vol.12
, pp. 619-625
-
-
Ocean, A.J.1
Vahdat, L.T.2
-
2
-
-
32244438054
-
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy
-
Hausheer FH, Schilsky RL, Bain S., Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 ; 33: 15-49.
-
(2006)
Semin Oncol
, vol.33
, pp. 15-49
-
-
Hausheer, F.H.1
Schilsky, R.L.2
Bain, S.3
Berghorn, E.J.4
Lieberman, F.5
-
3
-
-
0036158822
-
Chemotherapy-induced peripheral neuropathy
-
Quasthoff S., Hartung HP Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 ; 249: 9-17.
-
(2002)
J Neurol
, vol.249
, pp. 9-17
-
-
Quasthoff, S.1
Hartung, H.P.2
-
4
-
-
0041621727
-
Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management
-
Verstappen CP, Heimans JJ, Hoekman K., Postma TJ Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003 ; 63: 1549-1563.
-
(2003)
Drugs
, vol.63
, pp. 1549-1563
-
-
Verstappen, C.P.1
Heimans, J.J.2
Hoekman, K.3
Postma, T.J.4
-
5
-
-
0025107308
-
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin
-
van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C., Neijt JP Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990 ; 66: 1697-1702.
-
(1990)
Cancer
, vol.66
, pp. 1697-1702
-
-
Van Der Hoop, R.G.1
Van Der Burg, M.E.2
Ten Bokkel Huinink, W.W.3
Van Houwelingen, C.4
Neijt, J.P.5
-
7
-
-
1442279918
-
Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy
-
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 ; 29: 387-392.
-
(2004)
Muscle Nerve
, vol.29
, pp. 387-392
-
-
Lehky, T.J.1
Leonard, G.D.2
Wilson, R.H.3
Grem, J.L.4
Floeter, M.K.5
-
8
-
-
0033767619
-
Risks and benefits of taxanes in breast and ovarian cancer
-
Michaud LB, Valero V., Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000 ; 23: 401-428.
-
(2000)
Drug Saf
, vol.23
, pp. 401-428
-
-
Michaud, L.B.1
Valero, V.2
Hortobagyi, G.3
-
10
-
-
29144478503
-
Peripheral neuropathy: A persisting challenge in paclitaxel-based regimens
-
Mielke S., Sparreboom A., Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer. 2006 ; 42: 24-30.
-
(2006)
Eur J Cancer
, vol.42
, pp. 24-30
-
-
Mielke, S.1
Sparreboom, A.2
Mross, K.3
-
11
-
-
0347319032
-
The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer
-
Guastalla JP, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003 ; 89: 16-22.
-
(2003)
Br J Cancer
, vol.89
, pp. 16-22
-
-
Guastalla, J.P.1
Dieras, V.2
-
12
-
-
33645736326
-
Peripheral neuropathy induced by microtubule-stabilizing agents
-
Lee JJ, Swain SM Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 ; 24: 1633-1642.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1633-1642
-
-
Lee, J.J.1
Swain, S.M.2
-
13
-
-
21844480293
-
CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
-
Seidman AD, Berry D., Cirrincione C., et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol ASCO Annual Meeting Proceedings. 2004 ; 22: 512.
-
(2004)
J Clin Oncol ASCO Annual Meeting Proceedings
, vol.22
, pp. 512
-
-
Seidman, A.D.1
Berry, D.2
Cirrincione, C.3
-
14
-
-
0032751111
-
Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project B-26
-
Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project B-26. J Clin Oncol. 1999 ; 17: 3403-3411.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3403-3411
-
-
Smith, R.E.1
Brown, A.M.2
Mamounas, E.P.3
-
15
-
-
27644562207
-
Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
-
Mielke S., Sparreboom A., Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005 ; 11: 4843-4850.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4843-4850
-
-
Mielke, S.1
Sparreboom, A.2
Steinberg, S.M.3
-
16
-
-
0029888797
-
Peripheral neurotoxicity induced by docetaxel
-
Hilkens PH, Verweij J., Stoter G., Vecht CJ, van Putten WL, van den Bent MJ Peripheral neurotoxicity induced by docetaxel. Neurology. 1996 ; 46: 104-108.
-
(1996)
Neurology
, vol.46
, pp. 104-108
-
-
Ph, H.1
Verweij, J.2
Stoter, G.3
Vecht, C.J.4
Van Putten, W.L.5
Van Den Bent, M.J.6
-
17
-
-
11344275310
-
Neurotoxicity of cancer chemotherapy
-
Dropcho EJ Neurotoxicity of cancer chemotherapy. Semin Neurol. 2004 ; 24: 419-426.
-
(2004)
Semin Neurol
, vol.24
, pp. 419-426
-
-
Dropcho, E.J.1
-
18
-
-
33744908019
-
Neurologic complications of cancer chemotherapy
-
Sul JK, DeAngelis LM Neurologic complications of cancer chemotherapy. Semin Oncol. 2006 ; 33: 324-332.
-
(2006)
Semin Oncol
, vol.33
, pp. 324-332
-
-
Sul, J.K.1
Deangelis, L.M.2
-
19
-
-
44349099891
-
Neurological toxicities associated with cancer chemotherapeutic agents
-
Slade JH Neurological toxicities associated with cancer chemotherapeutic agents. US Pharm. 2005 ; 4: 3-18.
-
(2005)
US Pharm
, vol.4
, pp. 3-18
-
-
Slade, J.H.1
-
20
-
-
34548417669
-
Neuropathy in multiple myeloma treated with thalidomide: A prospective study
-
Plasmati R., Pastorelli F., Cavo M., et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007 ; 69: 573-581.
-
(2007)
Neurology
, vol.69
, pp. 573-581
-
-
Plasmati, R.1
Pastorelli, F.2
Cavo, M.3
-
21
-
-
2942737155
-
Thalidomide neuropathy: Too much or too long
-
Apfel SC, Zochodne DW Thalidomide neuropathy: too much or too long. Neurology. 2004 ; 62: 2158-2159.
-
(2004)
Neurology
, vol.62
, pp. 2158-2159
-
-
Apfel, S.C.1
Zochodne, D.W.2
-
22
-
-
33749051832
-
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
-
Mileshkin L., Stark R., Day B., Seymour JF, Zeldis JB, Prince HM Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006 ; 24: 4507-4514.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4507-4514
-
-
Mileshkin, L.1
Stark, R.2
Day, B.3
Seymour, J.F.4
Zeldis, J.B.5
Prince, H.M.6
-
23
-
-
0036446745
-
Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients
-
Bastuji-Garin S., Ochonisky S., Bouche P., et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002 ; 119: 1020-1026.
-
(2002)
J Invest Dermatol
, vol.119
, pp. 1020-1026
-
-
Bastuji-Garin, S.1
Ochonisky, S.2
Bouche, P.3
-
24
-
-
0037168803
-
Thalidomide-induced neuropathy
-
Chaudhry V., Cornblath DR, Corse A., Freimer M., Simmons-O'Brien E., Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002 ; 59: 1872-1875.
-
(2002)
Neurology
, vol.59
, pp. 1872-1875
-
-
Chaudhry, V.1
Cornblath, D.R.2
Corse, A.3
Freimer, M.4
Simmons-O'Brien, E.5
Vogelsang, G.6
-
25
-
-
44349115124
-
-
Cambridge, MA : Millennium Pharmaceuticals Inc;
-
Velcade [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc ; 2007.
-
(2007)
Velcade [Prescribing Information]
-
-
-
26
-
-
31444442200
-
A practical update on the use of bortezomib in the management of multiple myeloma
-
San Miguel J., Blade J., Boccadoro M., et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006 ; 11: 51-61.
-
(2006)
Oncologist
, vol.11
, pp. 51-61
-
-
San Miguel, J.1
Blade, J.2
Boccadoro, M.3
-
27
-
-
33746010219
-
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
-
Richardson PG, Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 ; 24: 3113-3120.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3113-3120
-
-
Richardson, P.G.1
Briemberg, H.2
Jagannath, S.3
-
28
-
-
21344435052
-
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
-
Oakervee HE, Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 ; 129: 755-762.
-
(2005)
Br J Haematol
, vol.129
, pp. 755-762
-
-
Oakervee, H.E.1
Popat, R.2
Curry, N.3
-
29
-
-
21344469223
-
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
-
Jagannath S., Durie B., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 ; 129: 776-783.
-
(2005)
Br J Haematol
, vol.129
, pp. 776-783
-
-
Jagannath, S.1
Durie, B.2
Wolf, J.3
-
30
-
-
33750953054
-
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study
-
Harousseau JL, Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006 ; 91: 1498-1505.
-
(2006)
Haematologica
, vol.91
, pp. 1498-1505
-
-
Harousseau, J.L.1
Attal, M.2
Leleu, X.3
-
31
-
-
34548183776
-
Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature
-
Badros A., Goloubeva O., Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007 ; 110: 1042-1048.
-
(2007)
Cancer
, vol.110
, pp. 1042-1048
-
-
Badros, A.1
Goloubeva, O.2
Dalal, J.S.3
-
32
-
-
33745796715
-
Life threatening motor neuropathy in association with bortezomib
-
Gupta S., Pagliuca A., Devereux S., Mufti GJ, Schey S. Life threatening motor neuropathy in association with bortezomib. Haematologica. 2006 ; 91: 1001.
-
(2006)
Haematologica
, vol.91
, pp. 1001
-
-
Gupta, S.1
Pagliuca, A.2
Devereux, S.3
Mufti, G.J.4
Schey, S.5
-
33
-
-
44349169561
-
-
Princeton, NJ: Bristol-Myers Squibb Company;
-
Ixempra [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company ; 2007.
-
(2007)
Ixempra [Prescribing Information]
-
-
-
34
-
-
36849071808
-
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
-
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 ; 25: 5210-5217.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5210-5217
-
-
Thomas, E.S.1
Gomez, H.L.2
Li, R.K.3
-
35
-
-
33846782923
-
Neuroprotection during chemotherapy: A systematic review
-
Walker M., Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol. 2007 ; 30: 82-92.
-
(2007)
Am J Clin Oncol
, vol.30
, pp. 82-92
-
-
Walker, M.1
Ni, O.2
-
36
-
-
22844448647
-
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy could it be predicted
-
Argyriou AA, Polychronopoulos P., Koutras A., et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy could it be predicted ? Support Care Cancer. 2005 ; 13: 647-651.
-
(2005)
Support Care Cancer
, vol.13
, pp. 647-651
-
-
Aa, A.1
Polychronopoulos, P.2
Koutras, A.3
-
37
-
-
15944426735
-
Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity
-
McDonald ES, Randon KR, Knight A., Windebank AJ Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005 ; 18: 305-313.
-
(2005)
Neurobiol Dis
, vol.18
, pp. 305-313
-
-
McDonald, E.S.1
Randon, K.R.2
Knight, A.3
Windebank, A.J.4
-
38
-
-
33846404174
-
Molecular mechanisms of resistance and toxicity associated with platinating agents
-
Rabik CA, Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 ; 33: 9-23.
-
(2007)
Cancer Treat Rev
, vol.33
, pp. 9-23
-
-
Rabik, C.A.1
Dolan, M.E.2
-
39
-
-
0031899544
-
Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy
-
Heinzlef O., Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998 ; 64: 667-669.
-
(1998)
J Neurol Neurosurg Psychiatry
, vol.64
, pp. 667-669
-
-
Heinzlef, O.1
Lotz, J.P.2
Roullet, E.3
-
40
-
-
24944507764
-
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
-
Jones SE, Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 ; 23: 5542-5551.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5542-5551
-
-
Jones, S.E.1
Erban, J.2
Overmoyer, B.3
-
41
-
-
34547447565
-
Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation
-
Boehmerle W., Zhang K., Sivula M., et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci USA. 2007 ; 104: 11103-11108.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 11103-11108
-
-
Boehmerle, W.1
Zhang, K.2
Sivula, M.3
-
42
-
-
1842786064
-
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
-
Flatters SJ, Bennett GJ Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004 ; 109: 150-161.
-
(2004)
Pain
, vol.109
, pp. 150-161
-
-
Flatters, S.J.1
Bennett, G.J.2
-
43
-
-
20444493101
-
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats
-
Persohn E., Canta A., Schoepfer S., et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005 ; 41: 1460-1466.
-
(2005)
Eur J Cancer
, vol.41
, pp. 1460-1466
-
-
Persohn, E.1
Canta, A.2
Schoepfer, S.3
-
44
-
-
0030037366
-
Motor neuropathy due to docetaxel and paclitaxel
-
Freilich RJ, Balmaceda C., Seidman AD, Rubin M., DeAngelis LM Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996 ; 47: 115-118.
-
(1996)
Neurology
, vol.47
, pp. 115-118
-
-
Freilich, R.J.1
Balmaceda, C.2
Seidman, A.D.3
Rubin, M.4
Deangelis, L.M.5
-
45
-
-
32944482677
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
-
Gradishar WJ, Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 ; 23: 7794-7803.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
-
46
-
-
0037309678
-
Neurologic complications of cancer therapy
-
Plotkin SR, Wen PY Neurologic complications of cancer therapy. Neurol Clin N Am. 2003 ; 21: 279-318.
-
(2003)
Neurol Clin N Am
, vol.21
, pp. 279-318
-
-
Plotkin, S.R.1
Wen, P.Y.2
-
47
-
-
0029801804
-
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - A phase II study
-
Fazeny B., Zifko U., Meryn S., Huber H., Grisold W., Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol. 1996 ; 39: 150-156.
-
(1996)
Cancer Chemother Pharmacol
, vol.39
, pp. 150-156
-
-
Fazeny, B.1
Zifko, U.2
Meryn, S.3
Huber, H.4
Grisold, W.5
Dittrich, C.6
-
48
-
-
2942729733
-
Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus
-
Briani C., Zara G., Rondinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004 ; 62: 2288-2290.
-
(2004)
Neurology
, vol.62
, pp. 2288-2290
-
-
Briani, C.1
Zara, G.2
Rondinone, R.3
-
49
-
-
0034947693
-
Thalidomide neuropathy in patients treated for metastatic prostate cancer
-
Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001 ; 24: 1050-1057.
-
(2001)
Muscle Nerve
, vol.24
, pp. 1050-1057
-
-
Molloy, F.M.1
Floeter, M.K.2
Syed, N.A.3
-
50
-
-
44349176449
-
-
Summit, NJ: Celgene Corporation Inc;
-
Revlimid [prescribing information]. Summit, NJ: Celgene Corporation Inc ; 2006.
-
(2006)
Revlimid [Prescribing Information]
-
-
-
51
-
-
33748114137
-
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies
-
Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne HA, Dalgleish AG Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer. 2006 ; 42: 2318-2325.
-
(2006)
Eur J Cancer
, vol.42
, pp. 2318-2325
-
-
Sharma, R.A.1
Steward, W.P.2
Daines, C.A.3
Knight, R.D.4
O'Byrne, H.A.5
Dalgleish, A.G.6
-
52
-
-
33847293709
-
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
-
Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007 ; 204: 317-325.
-
(2007)
Exp Neurol
, vol.204
, pp. 317-325
-
-
Cavaletti, G.1
Gilardini, A.2
Canta, A.3
-
54
-
-
3042523914
-
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
-
Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004 ; 10: 4055-4061.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4055-4061
-
-
Gamelin, L.1
Boisdron-Celle, M.2
Delva, R.3
-
55
-
-
34548544244
-
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity
-
Hochster H., Grothey A., Childs B., et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007 ; 25: 4028-4029.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4028-4029
-
-
Hochster, H.1
Grothey, A.2
Childs, B.3
|